Indeed, recent studies indicate that mortalin could serve as a prognostic and predictive marker of cancer invasiveness as its up-regulation has been detected in a variety of malignancies, such as brain tumors, hepatocellular carcinoma, colon carcinoma, breast cancer, and leukemia. Here, HSPA9 is linked to breast carcinoma.